Bioventus (NYSE:BVS) Updates FY 2025 Earnings Guidance

Bioventus (NYSE:BVS) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus EPS estimate of 0.570. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $566.8 million.

Bioventus Stock Performance

Shares of Bioventus stock opened at $6.56 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus has a 12 month low of $5.81 and a 12 month high of $14.38. The stock’s fifty day moving average price is $6.94 and its 200-day moving average price is $6.87. The firm has a market cap of $542.37 million, a P/E ratio of -10.75 and a beta of 0.81.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald began coverage on shares of Bioventus in a research note on Monday, July 7th. They set an “overweight” rating and a $12.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.75.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently bought and sold shares of the company. Engineers Gate Manager LP acquired a new position in shares of Bioventus during the second quarter worth $394,000. Boothbay Fund Management LLC purchased a new stake in shares of Bioventus in the second quarter worth about $554,000. Kent Lake PR LLC purchased a new position in Bioventus during the second quarter valued at approximately $2,317,000. Marshall Wace LLP lifted its holdings in Bioventus by 32.5% in the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock valued at $1,401,000 after acquiring an additional 51,951 shares during the period. Finally, Rhumbline Advisers boosted its position in Bioventus by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after purchasing an additional 11,133 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.